319 related articles for article (PubMed ID: 11112479)
21. Circulating vaccine-derived polioviruses: current state of knowledge.
Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
[TBL] [Abstract][Full Text] [Related]
22. [Genetic evolution of poliovirus: success and difficulties in the eradication of paralytic poliomyelitis].
Blondel B; Autret A; Brisac C; Pelletier I; Martin-Latil S; Jegouic S; Bessaud M; Joffret ML; Balanant J; Colbère-Garapin F; Delpeyroux F
Med Trop (Mars); 2008 Apr; 68(2):189-202. PubMed ID: 18630055
[TBL] [Abstract][Full Text] [Related]
23. Comparison of microarray-predicted closest genomes to sequencing for poliovirus vaccine strain similarity and influenza A phylogeny.
Maurer-Stroh S; Lee CW; Patel C; Lucero M; Nohynek H; Sung WK; Murad C; Ma J; Hibberd ML; Wong CW; Simões EA
Diagn Microbiol Infect Dis; 2016 Mar; 84(3):203-6. PubMed ID: 26658310
[TBL] [Abstract][Full Text] [Related]
24. [Investigation of a Patient with Pre-vaccine-derived Poliovirus in Shandong Province, China].
Lin X; Liu Y; Wang S; Zhang Xiao ; Song L; Tao Z; Ji F; Xiong P; Xu A
Bing Du Xue Bao; 2015 Sep; 31(5):542-7. PubMed ID: 26738293
[TBL] [Abstract][Full Text] [Related]
25. Characterization of mutations in the VP(1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran.
Rahimi P; Tabatabaie H; Gouya MM; Zahraie M; Mahmudi M; Ziaie A; Rad KS; Shahmahmudi Sh; Musavi T; Azad TM; Nategh R
J Clin Virol; 2007 Aug; 39(4):304-7. PubMed ID: 17590391
[TBL] [Abstract][Full Text] [Related]
26. [End phase challenges of poliomyelitis eradication programme realization].
Jarzabek Z
Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
[TBL] [Abstract][Full Text] [Related]
27. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota.
Alexander JP; Ehresmann K; Seward J; Wax G; Harriman K; Fuller S; Cebelinski EA; Chen Q; Jorba J; Kew OM; Pallansch MA; Oberste MS; Schleiss M; Davis JP; Warshawsky B; Squires S; Hull HF;
J Infect Dis; 2009 Feb; 199(3):391-7. PubMed ID: 19090774
[TBL] [Abstract][Full Text] [Related]
28. WHO prepares for final push to rid the world of polio.
Butler D
Nature; 2003 Aug; 424(6949):604. PubMed ID: 12904751
[No Abstract] [Full Text] [Related]
29. [Analysis on identification and genetic character of type I vaccine-derived poliovirus in Shanxi province in 2007].
Yan DM; Zhu SL; Zhang Y
Zhongguo Yi Miao He Mian Yi; 2009 Apr; 15(2):131-4. PubMed ID: 20077658
[TBL] [Abstract][Full Text] [Related]
30. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.
Burns CC; Shaw J; Jorba J; Bukbuk D; Adu F; Gumede N; Pate MA; Abanida EA; Gasasira A; Iber J; Chen Q; Vincent A; Chenoweth P; Henderson E; Wannemuehler K; Naeem A; Umami RN; Nishimura Y; Shimizu H; Baba M; Adeniji A; Williams AJ; Kilpatrick DR; Oberste MS; Wassilak SG; Tomori O; Pallansch MA; Kew O
J Virol; 2013 May; 87(9):4907-22. PubMed ID: 23408630
[TBL] [Abstract][Full Text] [Related]
31. Problems with the oral polio vaccine.
Bhasin VK
Nat Med; 2008 Jan; 14(1):9. PubMed ID: 18180708
[No Abstract] [Full Text] [Related]
32. Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
Horaud F
Dev Biol Stand; 1993; 78():149-54; discussion 154-5. PubMed ID: 8388825
[No Abstract] [Full Text] [Related]
33. Molecular epidemiology of wild poliovirus type 1 circulation in West and Central Africa, from 1997 to 1999, using genotyping with a restriction fragment length polymorphism assay.
Gouandjika-Vasilache I; Burns CC; Gumede N; Guillot S; Ménard D; Dosseh A; Akoua-Koffi C; Pallansch MA; Kew OM; Delpeyroux F
Arch Virol; 2008; 153(3):409-16. PubMed ID: 18060590
[TBL] [Abstract][Full Text] [Related]
34. [Genetic changes in strains of poliovirus type 2 isolated from patients with vaccine-associated paralytic poliomyelitis].
Sosa-Díaz RY; Más-Lago P; Valdés-Ramírez O; Sarmiento-Pérez L
Rev Neurol; 2003 May 1-15; 36(9):812-6. PubMed ID: 12717666
[TBL] [Abstract][Full Text] [Related]
35. [On an epidemic outbreak of poliomyelitis, type 3, in the Voivode County of Poznań in 1968].
Walter T
Zentralbl Bakteriol Orig; 1969; 211(2):162-6. PubMed ID: 4318358
[No Abstract] [Full Text] [Related]
36. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
[TBL] [Abstract][Full Text] [Related]
37. Infectious disease. Vaccine-related polio outbreak in Nigeria raises concerns.
Roberts L
Science; 2007 Sep; 317(5846):1842. PubMed ID: 17901301
[No Abstract] [Full Text] [Related]
38. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.
Macadam AJ; Pollard SR; Ferguson G; Skuce R; Wood D; Almond JW; Minor PD
Virology; 1993 Jan; 192(1):18-26. PubMed ID: 8390752
[TBL] [Abstract][Full Text] [Related]
39. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
40. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
